---
title: Neoadjuvant chemo- or chemo-radiation-therapy of pancreatic ductal adenocarcinoma
  differentially shift ECM composition, complement activation, energy metabolism and
  ribosomal proteins of the residual tumor mass
date: '2024-02-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38353498/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240214170735&v=2.18.0
source: heidelberg[Affiliation]
description: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, often
  diagnosed at stages that dis-qualify for surgical resection. Neoadjuvant therapies
  offer potential tumor regression and improved resectability. Although features of
  the tumor biology (e.g., molecular markers) may guide adjuvant therapy, biological
  alterations after neoadjuvant therapy remain largely unexplored. We performed mass
  spectrometry to characterize the proteomes of 67 PDAC resection specimens of patients
  ...
disable_comments: true
---
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, often diagnosed at stages that dis-qualify for surgical resection. Neoadjuvant therapies offer potential tumor regression and improved resectability. Although features of the tumor biology (e.g., molecular markers) may guide adjuvant therapy, biological alterations after neoadjuvant therapy remain largely unexplored. We performed mass spectrometry to characterize the proteomes of 67 PDAC resection specimens of patients ...